NIH Alzheimer’s Initiative To Promote Neuroimaging, Identify Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
Program aimed at speeding Alzheimer’s drug development through neuroimaging and biomarkers is launched by the National Institute on Aging through a five-year, $60 mil. project. Large pharma companies are contributing funds to a multi-site study of 800 subjects.